NCT07203391

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

TRIUMPH - Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (estimated)
• Sponsor: St Vincent's Hospital, Sydney · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a combination study of Tebentafusp and the PI3Kdelta inhibitor, Roginolisib

Detailed description

Based on the established activity of Tebentafusp, and the promising action of Roginolisib, this trial combines the two drugs from cycle 4 onwards in patients with metastatic uveal melanoma

Conditions

• Uveal Melanoma, Metastatic

Interventions

Type	Name	Description
DRUG	roginolisib	Investigational combination - initially at 40mg (Dose 1) then 80mg (Dose 2)

Timeline

• Start date: 2025-12-01
• Primary completion: 2027-12-01
• Completion: 2029-12-01
• First posted: 2025-10-02
• Last updated: 2025-10-02

Locations

2 sites across 1 country: Australia